Vitamin D supplementation for the prevention of type 2 diabetes in overweight adults: study protocol for a randomized controlled trial

Barbora de Courten, Aya Mousa, Negar Naderpoor, Helena Teede, Maximilian P J de Courten, Robert Scragg, Barbora de Courten, Aya Mousa, Negar Naderpoor, Helena Teede, Maximilian P J de Courten, Robert Scragg

Abstract

Background: Despite Australia's sunny climate, low vitamin D levels are increasingly prevalent. Sun exposure is limited by long working hours, an increase in time spent indoors, and sun protection practices, and there is limited dietary vitamin D fortification. While the importance of vitamin D for bone mineralization is well known, its role as a protective agent against chronic diseases, such as type 2 diabetes and cardiovascular disease, is less understood. Observational and limited intervention studies suggest that vitamin D might improve insulin sensitivity and secretion, mainly via its anti-inflammatory properties, thereby decreasing the risk of development and progression of type 2 diabetes. The primary aim of this trial is to investigate whether improved plasma concentrations of 25-hydroxyvitamin D (25(OH)D), obtained through vitamin D supplementation, will increase insulin sensitivity and insulin secretion. A secondary aim is to determine whether these relationships are mediated by a reduction in underlying subclinical inflammation associated with obesity.

Methods/design: Fifty overweight but otherwise healthy nondiabetic adults between 18 and 60 years old, with low vitamin D levels (25(OH)D < 50 nmol/l), will be randomly assigned to intervention or placebo. At baseline, participants will undergo a medical review and anthropometric measurements, including dual X-ray absorptiometry, an intravenous glucose tolerance test, muscle and fat biopsies, a hyperinsulinemic euglycemic clamp, and questionnaires assessing diet, physical activity, sun exposure, back and knee pain, and depression. The intervention group will receive a first dose of 100,000 IU followed by 4,000 IU vitamin D (cholecalciferol) daily, while the placebo group will receive apparently identical capsules, both for a period of 16 weeks. All measurements will be repeated at follow-up, with the primary outcome measure expressed as a change from baseline in insulin sensitivity and secretion for the intervention group compared with the placebo group. Secondary outcome measures will compare changes in anthropometry, cardiovascular risk factors, and inflammatory markers.

Discussion: The trial will provide much needed clinical evidence on the impact of vitamin D supplementation on insulin resistance and secretion and its underlying mechanisms, which are relevant for the prevention and management of type 2 diabetes.

Trial registration: Clinicaltrials.gov ID: NCT02112721 .

Figures

Fig. 1
Fig. 1
Trial protocol. DEXA, dual X-ray absorptiometry; FBC, full blood count; IVGTT, intravenous glucose tolerance test; LFT, liver function test; OGTT, oral glucose tolerance test; UEC, urea, electrolytes, creatinine
Fig. 2
Fig. 2
Study timeline. IVGTT, intravenous glucose tolerance test; OGTT, oral glucose tolerance test

References

    1. Holick MF. Vitamin D, status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19(2):73–8. doi: 10.1016/j.annepidem.2007.12.001.
    1. Hypponen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr. 2007;85(3):860–8.
    1. Pittas A, Lau J, Hu F, Dawson-Hughes B. The role of Vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92:2017–29. doi: 10.1210/jc.2007-0298.
    1. Grandi NC, Breitling LP, Brenner H. Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev Med. 2010;51(3–4):228–33. doi: 10.1016/j.ypmed.2010.06.013.
    1. Joergensen C, Gall MA, Schmedes A, Tarnow L, Parving HH, Rossing P. Vitamin D levels and mortality in type 2 diabetes. Diabetes Care. 2010;33(10):2238–43. doi: 10.2337/dc10-0582.
    1. Sinclair C. Risks and benefits of sun exposure: implications for public health practice based on the Australian experience. Prog Biophys Mol Biol. 2006;92(1):173–8. doi: 10.1016/j.pbiomolbio.2006.02.006.
    1. Holick MF. Vitamin D, deficiency in 2010: health benefits of vitamin D and sunlight: a D-bate. Nat Rev Endocrinol. 2011;7(2):73–5. doi: 10.1038/nrendo.2010.234.
    1. Government A. Department of Health and Aging, National Health and Medical Research Council. Nutrient reference values for Australia and New Zealand: executive summary. Canberra: NHMRC; 2006.
    1. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–8. doi: 10.1210/jc.2010-2704.
    1. Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr. 2008;87(3):688–91.
    1. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr. 2001;73(2):288–94.
    1. Need AG, O’Loughlin PD, Horowitz M, Nordin BE. Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol. 2005;62(6):738–41. doi: 10.1111/j.1365-2265.2005.02288.x.
    1. Liu E, Meigs JB, Pittas AG, McKeown NM, Economos CD, Booth SL, et al. Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr. 2009;139(2):329–34. doi: 10.3945/jn.108.093831.
    1. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr. 2004;79(5):820–5.
    1. Ou HY, Karnchanasorn R, Lee LZ, Chiu KC. Interaction of BMI with vitamin D and insulin sensitivity. Eur J Clin Investig. 2011;41(11):1195–201. doi: 10.1111/j.1365-2362.2011.02525.x.
    1. Hypponen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care. 2006;29(10):2244–6. doi: 10.2337/dc06-0946.
    1. Pinelli NR, Jaber LA, Brown MB, Herman WH. Serum 25-hydroxy vitamin D and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care. 2010;33(6):1373–5. doi: 10.2337/dc09-2199.
    1. Gannage-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol. 2009;160(6):965–71. doi: 10.1530/EJE-08-0952.
    1. Burgaz A, Byberg L, Rautiainen S, Orsini N, Hakansson N, Arnlov J, et al. Confirmed hypertension and plasma 25(OH)D concentrations amongst elderly men. J Intern Med. 2011;269(2):211–8. doi: 10.1111/j.1365-2796.2010.02309.x.
    1. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011;50(4):303–12. doi: 10.1016/j.plipres.2011.05.001.
    1. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes. 2008;57(10):2619–25. doi: 10.2337/db08-0593.
    1. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, et al. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study) Diabetes Care. 2011;34(5):1133–8. doi: 10.2337/dc10-2167.
    1. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307–14. doi: 10.7326/0003-4819-152-5-201003020-00009.
    1. Zittermann A. Vitamin D, and cardiovascular disease. Anticancer Res. 2014;34(9):4641–8.
    1. Zittermann A, Prokop S. The role of vitamin D for cardiovascular disease and overall mortality. Adv Exp Med Biol. 2014;810:106–19.
    1. Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL, et al. Clinical review: effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3551–60. doi: 10.1210/jc.2014-2136.
    1. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51(2):455–61. doi: 10.2337/diabetes.51.2.455.
    1. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev. 2008;29(1):42–61. doi: 10.1210/er.2007-0015.
    1. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab. 2008;10(3):185–97. doi: 10.1111/j.1463-1326.2007.00710.x.
    1. Sanghi D, Mishra A, Sharma AC, Singh A, Natu SM, Agarwal S, et al. Does vitamin D improve osteoarthritis of the knee: a randomized controlled pilot trial. Clin Orthop Relat Res. 2013;471(11):3556–62. doi: 10.1007/s11999-013-3201-6.
    1. Shaw J, Tanama S. Diabetes: the silent pandemic and its impact on Australia. Canberra: Diabetes Australia; 2012.
    1. Kupferschmidt K. Uncertain verdict as vitamin D goes on trial. Science. 2012;337(6101):1476–8. doi: 10.1126/science.337.6101.1476.
    1. Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr. 2011;65(9):1005–15. doi: 10.1038/ejcn.2011.118.
    1. Arunabh S, Pollack S, Yeh J, Aloia JF. Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab. 2003;88(1):157–61. doi: 10.1210/jc.2002-020978.
    1. Bischof MG, Heinze G, Vierhapper H. Vitamin D status and its relation to age and body mass index. Horm Res. 2006;66(5):211–5. doi: 10.1159/000094932.
    1. Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract. 2003;57(4):258–61.
    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>;2-S.
    1. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–95. doi: 10.1249/01.MSS.0000078924.61453.FB.
    1. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8(1):77–100. doi: 10.1016/0272-7358(88)90050-5.
    1. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85(1):6–18.
    1. Svendsen OL, Haarbo J, Hassager C, Christiansen C. Accuracy of measurements of body composition by dual-energy X-ray absorptiometry in vivo. Am J Clin Nutr. 1993;57(5):605–8.
    1. Food Standard Australia New Zealand. NUTTAB 2010.
    1. Norman AW. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am J Clin Nutr. 1998;67(6):1108–10.
    1. Rosso S, Minarro R, Schraub S, Tumino R, Franceschi S, Zanetti R. Reproduceability of skin characteristic measurements and reported sun exposure history. Int J Epidemiol. 2002;31:439–46. doi: 10.1093/ije/31.2.439.
    1. Barger-Lux MJ, Heaney RP. Effects of above average summer sun exposure on serum 25-hydroxyvitamin D and calcium absorption. J Clin Endocrinol Metab. 2002;87(11):4952–6. doi: 10.1210/jc.2002-020636.
    1. Carmody DP. Psychometric characteristics of the Beck Depression Inventory-II with college students of diverse ethnicity. Int J Psychiatry Clin Pract. 2005;9(1):22–8. doi: 10.1080/13651500510014800.
    1. Schotte CK, Maes M, Cluydts R, De Doncker D, Cosyns P. Construct validity of the Beck Depression Inventory in a depressive population. J Affect Disord. 1997;46(2):115–25. doi: 10.1016/S0165-0327(97)00094-3.
    1. Chung HK, Cho Y, Choi S, Shin MJ. The association between serum 25-hydroxyvitamin D concentrations and depressive symptoms in Korean adults: findings from the fifth Korea National Health and Nutrition Examination Survey 2010. PLoS One. 2014;9(6):e99185. doi: 10.1371/journal.pone.0099185.
    1. Howland RH. Vitamin D, and depression. J Psychosoc Nurs Ment Health Serv. 2011;49(2):15–8. doi: 10.3928/02793695-20110111-02.
    1. Siegert RJ, Tennant A, Turner-Stokes L. Rasch analysis of the Beck Depression Inventory-II in a neurological rehabilitation sample. Disabil Rehabil. 2010;32(1):8–17. doi: 10.3109/09638280902971398.
    1. Al-Jarallah K, Shehab D, Abraham M, Mojiminiyi OA, Abdella NA. Musculoskeletal pain: should physicians test for vitamin D level? Int J Rheum Dis. 2013;16(2):193–7. doi: 10.1111/1756-185X.12066.
    1. Cranney A, Horsley T, O’Donnell S, Weiler H, Puil L, Ooi D, et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess. 2007;158:1–235.
    1. Hamman RF, Horton E, Barrett-Connor E, Bray GA, Christophi C, Crandall J, et al. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcome Study (DPPOS) Diabetes. 2015;64:989–98. doi: 10.2337/db14-0333.
    1. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient: a randomised, placebo-controlled trial. Br J Nutr. 2010;103(4):549–55. doi: 10.1017/S0007114509992017.
    1. Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor δ gene is a primary target of 1α,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol. 2005;349(2):248–60. doi: 10.1016/j.jmb.2005.03.060.
    1. Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J. 2000;47(4):383–91. doi: 10.1507/endocrj.47.383.
    1. Maestro B, Molero S, Bajo S, Davila N, Calle C. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D3. Cell Biochem Funct. 2002;20(3):227–32. doi: 10.1002/cbf.951.
    1. Cavalier E, Delanaye P, Souberbielle JC, Radermecker RP. Vitamin D and type 2 diabetes mellitus: where do we stand? Diabetes Metab. 2011;37(4):265–72. doi: 10.1016/j.diabet.2011.01.001.
    1. Dutta D, Mondal SA, Choudhuri S, Maisnam I, Hasanoor Reza AH, Bhattacharya B, et al. Vitamin-D supplementation in prediabetes reduced progression to type 2 diabetes and was associated with decreased insulin resistance and systemic inflammation: an open label randomized prospective study from Eastern India. Diabetes Res Clin Pract. 2014;103:e18–23. doi: 10.1016/j.diabres.2013.12.044.
    1. Pratley RE, Weyer C. Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion. Curr Diab Rep. 2002;2(3):242–8. doi: 10.1007/s11892-002-0090-6.
    1. Mark AB, Poulsen MW, Andersen S, Andersen JM, Bak MJ, Ritz C, et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care. 2014;37(1):88–95. doi: 10.2337/dc13-0842.
    1. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334–8. doi: 10.1006/abbi.1999.1605.
    1. Baz-Hecht M, Goldfine AB. The impact of vitamin D deficiency on diabetes and cardiovascular risk. Curr Opin Endocrinol Diabetes Obes. 2010;17(2):113–9. doi: 10.1097/MED.0b013e3283372859.
    1. Farmer JA. Renin angiotensin system and ASCVD. Curr Opin Cardiol. 2000;15(3):141–50. doi: 10.1097/00001573-200005000-00004.
    1. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243–8. doi: 10.1016/j.jacc.2005.01.015.
    1. Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M. Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr. 2014;100(3):746–55. doi: 10.3945/ajcn.113.082602.
    1. Vaidya A, Forman JP. Vitamin D and vascular disease: the current and future status of vitamin D therapy in hypertension and kidney disease. Curr Hypertens Rep. 2012;14(2):111–9. doi: 10.1007/s11906-012-0248-9.
    1. Sourris KC, Lyons JG, Dougherty SL, Chand V, Straznicky NE, Schlaich MP, et al. Plasma advanced glycation end products (AGEs) and NF-κB activity are independent determinants of diastolic and pulse pressure. Clin Chem Lab Med. 2014;52(1):129–38. doi: 10.1515/cclm-2012-0850.
    1. Al-Daghri NM, Alkharfy KM, Al-Saleh Y, Al-Attas OS, Alokail MS, Al-Othman A, et al. Modest reversal of metabolic syndrome manifestations with vitamin D status correction: a 12-month prospective study. Metab Clin Exp. 2012;61(5):661–6. doi: 10.1016/j.metabol.2011.09.017.
    1. Carbone LD, Rosenberg EW, Tolley EA, Holick MF, Hughes TA, Watsky MA, et al. 25-Hydroxyvitamin D, cholesterol, and ultraviolet irradiation. Metab Clin Exp. 2008;57(6):741–8. doi: 10.1016/j.metabol.2008.01.011.
    1. Wehmeier KR, Mazza A, Hachem S, Ligaray K, Mooradian AD, Wong NC, et al. Differential regulation of apolipoprotein A-I gene expression by vitamin D receptor modulators. Biochim Biophys Acta. 2008;1780(2):264–73. doi: 10.1016/j.bbagen.2007.11.008.
    1. Wolden-Kirk H, Overbergh L, Christesen HT, Brusgaard K, Mathieu C. Vitamin D and diabetes: its importance for beta cell and immune function. Mol Cell Endocrinol. 2011;347(1–2):106–20. doi: 10.1016/j.mce.2011.08.016.
    1. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-dihydroxyvitamin D3 works as anti-inflammatory. Diabetes Res Clin Pract. 2007;77(1):47–57. doi: 10.1016/j.diabres.2006.10.007.
    1. Deb DK, Chen Y, Zhang Z, Zhang Y, Szeto FL, Wong KE, et al. 1,25-dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-κB pathway. Am J Physiol Renal Physiol. 2009;296(5):F1212–8. doi: 10.1152/ajprenal.00002.2009.
    1. Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ. 1α,25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-κB-mediated interleukin-8 gene expression. Eur J Biochem. 1997;250(1):63–71. doi: 10.1111/j.1432-1033.1997.00063.x.
    1. Szeto FL, Sun J, Kong J, Duan Y, Liao A, Madara JL, et al. Involvement of the vitamin D receptor in the regulation of NF-κB activity in fibroblasts. J Steroid Biochem Mol Biol. 2007;103(3–5):563–6. doi: 10.1016/j.jsbmb.2006.12.092.
    1. Podsakoff PM, MacKenzie SB, Lee JY, Podsakoff NP. Common method biases in behavioral research: a critical review of the literature and recommended remedies. J Appl Psychol. 2003;88(5):879–903. doi: 10.1037/0021-9010.88.5.879.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться